Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | Amyloid reduction as a surrogate endpoint in Alzheimer’s disease trials: insights from DIAN-TU

Guoqiao Wang, PhD, Washington University School of Medicine, St Louis, MO, addresses the utilization of amyloid reduction as a surrogate endpoint in Alzheimer’s disease (AD) clinical trials and its correlation with clinical cognitive benefits, with a focus on insights from the DIAN-TU trial (NCT05269394). This controversial topic stems from trials in which amyloid reduction in response to treatment did not translate to cognitive improvements, prompting criticism of the amyloid hypothesis. While the DIAN-TU trial initially showed no treatment effect, the application of latent class analysis revealed an association between amyloid reduction and cognitive benefits. This interview took place at the CTAD 2023 conference in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Guoqiao Wang is the biostatistics core co-leader for the DIAN-TU and supported by fundings from NIH/NIA, Alzheimer’s Association, Eli Lilly and Company, F. Hoffman-LaRoche Ltd., Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, GHR Foundation, an anonymous organization. Cogstate and Signant offered in-kind support. He reports serving on a Data Safety Committee for Eli Lilly and Company and statistical consultant for Alector, Inc.